Remix Therapeutics, a clinical stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, entered a collaboration and license agreement with Roche for the discovery and development of small molecules that modulate RNA processing using Remix’s REMaster drug discovery platform.   Remix will receive $30 million upfront and is eligible to receive up to $12 million in near-term milestone payments, as well as preclinica...